UCSF spinout Kopra Bio secures $9.1M to advance virus therapy for glioblastoma in China

Kopra Bio, a biotechnology company spun out of the University of California, San Francisco, announced it has raised $9.1 million in financing. The capital will be used to move its experimental virus‑based treatment into early testing.

The funding targets a novel approach to glioblastoma, a highly aggressive brain tumor that typically evades the immune system and resists standard immunotherapies. Researchers hope the engineered virus can stimulate an immune response that overcomes this resistance.

The planned studies will be conducted in China, where the company aims to evaluate safety and efficacy in patients. Success could open a new therapeutic avenue for a disease with limited treatment options.